These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 30133144

  • 1. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P, Zhang J, Shang C, Zhang L.
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [Abstract] [Full Text] [Related]

  • 2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 3. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 4. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L, Hou F, Liu Y, Li W, Zhang H.
    J Natl Compr Canc Netw; 2021 Nov 11; 20(1):2-6. PubMed ID: 34763318
    [Abstract] [Full Text] [Related]

  • 5. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec 11; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S.
    Cancer Sci; 2015 Mar 11; 106(3):244-52. PubMed ID: 25581823
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.
    Huang T, Engelmann BJ, Morgan RM, Absher KJ, Kolesar JM, Villano JL.
    Cancer Chemother Pharmacol; 2018 May 11; 81(5):965-968. PubMed ID: 29610932
    [Abstract] [Full Text] [Related]

  • 16. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S.
    Anticancer Drugs; 2018 Nov 11; 29(10):935-943. PubMed ID: 30074936
    [Abstract] [Full Text] [Related]

  • 17. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
    Zhong JM, Zhang GF, Lin L, Li DY, Liu ZH.
    Lung Cancer; 2020 Jul 11; 145():211-212. PubMed ID: 32409002
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.